146 related articles for article (PubMed ID: 30888476)
1. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies.
Dercle L; Mokrane FZ; Schiano de Colella JM; Stamatoullas A; Morschhauser F; Brice P; Ghesquières H; Casasnovas O; Chen A; Manson G; Houot R
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1391-1392. PubMed ID: 30888476
[No Abstract] [Full Text] [Related]
2.
Dercle L; Seban RD; Lazarovici J; Schwartz LH; Houot R; Ammari S; Danu A; Edeline V; Marabelle A; Ribrag V; Michot JM
J Nucl Med; 2018 Jan; 59(1):15-24. PubMed ID: 28596157
[TBL] [Abstract][Full Text] [Related]
3. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
4. Performance of CT Compared with
Mokrane FZ; Chen A; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Duléry R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Houot R; Dercle L
Radiology; 2020 Jun; 295(3):651-661. PubMed ID: 32286191
[TBL] [Abstract][Full Text] [Related]
5. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma.
Dercle L; Ammari S; Seban RD; Schwartz LH; Houot R; Labaied N; Mokrane FZ; Lazarovici J; Danu A; Marabelle A; Ribrag V; Michot JM
Eur J Cancer; 2018 Mar; 91():136-144. PubMed ID: 29360605
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT Imaging of Hodgkin Lymphoma in a Child with Common Variable Immunodeficiency.
Tatci E; Biner IU; Tanyildiz HG; Ozmen O; Gokcek A; Sahin G; Tazeler Z
J Nucl Med Technol; 2016 Dec; 44(4):259-260. PubMed ID: 27363447
[TBL] [Abstract][Full Text] [Related]
8. Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas.
Lopci E; Meignan M
PET Clin; 2020 Jan; 15(1):23-34. PubMed ID: 31735299
[TBL] [Abstract][Full Text] [Related]
9. Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma.
Quéro L; Gilardin L; Fumagalli I; Martin V; Guillerm S; Bauduceau O; Kirova YM; Hennequin C; Brice P
Cancer Radiother; 2019 Apr; 23(2):132-137. PubMed ID: 30733172
[TBL] [Abstract][Full Text] [Related]
10. Role of FDG PET-CT in the treatment management of Hodgkin lymphoma.
Berriolo-Riedinger A; Becker S; Casasnovas O; Vander Borght T; Édeline V
Cancer Radiother; 2018 Sep; 22(5):393-400. PubMed ID: 30033076
[TBL] [Abstract][Full Text] [Related]
11. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
12. An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
Wight JC; Hawkes EA; Berlangieri SU; Khor R; Grigg AP
Leuk Lymphoma; 2018 Nov; 59(11):2749-2751. PubMed ID: 29569979
[No Abstract] [Full Text] [Related]
13. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
14. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab Immunotherapy-Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer.
T T; Goyal H; Singh H; Das CK; Sekar A; Kumar R
Clin Nucl Med; 2022 Jul; 47(7):e513-e514. PubMed ID: 35439194
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-Induced Pneumonitis in Patient With Metastatic Melanoma Showing Complete Remission on 18F-FDG PET/CT.
Razzouk-Cadet M; Picard A; Grangeon-Chapon C; Lacour JP; Montaudié H
Clin Nucl Med; 2019 Oct; 44(10):806-807. PubMed ID: 31306191
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Reinhardt MJ; Herkel C; Altehoefer C; Finke J; Moser E
Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
19.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis.
Adams HJ; Kwee TC
Ann Hematol; 2016 Apr; 95(5):695-706. PubMed ID: 26931115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
